HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype.

Abstract
The family of multidrug resistance-associated proteins (MRPs) belongs to the superfamily of adenosine triphosphate-binding-cassette (ABC) transporters, which have the ability to function as outward pumps for chemotherapeutic drugs and therefore might be involved in drug resistance. In this study the expression of the MRP2, MRP3, MRP4, MRP5, and SMRP genes was measured using TaqMan real-time polymerase chain reaction (PCR) in 103 children with previously untreated acute lymphoblastic leukemia (ALL) (precursor B-cell ALL [B-ALL], n = 71; T-cell ALL [T-ALL], n = 32). All 5 genes were expressed with a great variability. Only MRP3 expression was associated with a significantly worse prognosis (P =.008). The median expression of MRP3 was 10-fold higher in T-ALL than in precursor B-ALL (P <.001) and 4-fold higher in male patients than in female patients (P <.001). The prognostic impact of MRP3 was independent of immunophenotype or sex. Higher levels of MRP3 were found in patients with a poor in vivo response to prednisone, but this could not be confirmed in an independent case-control study (40 patients) for prednisone response. In healthy donors, the median expression of MRP4 was 4-fold higher in bone marrow and 8-fold higher in CD34+ stem cells compared with peripheral blood (P =.002). Our results suggest that MRP3 is involved in drug resistance in childhood ALL. It therefore represents an interesting target to overcome multidrug resistance. High levels of MRP3 could possibly be the reason for the poorer prognosis of male patients or patients who have T-ALL. Similar to other members of the family of ABC transporters, MRP4 seems to be a marker for immature stem cells.
AuthorsDaniel Steinbach, Susann Wittig, Gunnar Cario, Susanne Viehmann, Angelika Mueller, Bernd Gruhn, Ralf Haefer, Felix Zintl, Axel Sauerbrey
JournalBlood (Blood) Vol. 102 Issue 13 Pg. 4493-8 (Dec 15 2003) ISSN: 0006-4971 [Print] United States
PMID12816874 (Publication Type: Comparative Study, Journal Article, Multicenter Study)
Chemical References
  • Multidrug Resistance-Associated Proteins
  • Neoplasm Proteins
  • RNA, Messenger
  • RNA, Neoplasm
  • multidrug resistance-associated protein 3
Topics
  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Drug Resistance, Multiple (genetics)
  • Drug Resistance, Neoplasm (genetics)
  • Female
  • Hematopoietic Stem Cells (metabolism)
  • Humans
  • Immunophenotyping
  • Infant
  • Leukemia-Lymphoma, Adult T-Cell (blood, drug therapy, mortality)
  • Leukocytes, Mononuclear (metabolism)
  • Male
  • Multidrug Resistance-Associated Proteins (blood, genetics)
  • Neoplasm Proteins (blood, genetics)
  • Neoplastic Stem Cells (metabolism)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (blood, drug therapy, mortality)
  • Prognosis
  • Proportional Hazards Models
  • RNA, Messenger (blood)
  • RNA, Neoplasm (blood)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Survival Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: